EPISODE · Feb 14, 2024 · 44 MIN
From Biopharma to Cannabis:The Intersection of Pharma and Pot with Seth Yakatan
from CannaBiz Conversations · host Sean Welsh and Seth Yakatan
In this episode of CannaBiz Conversations, host Sean Welsh interviews Seth Yakatan, a prominent figure in the cannabis industry. Seth shares his cannabis origin story, recounting how he first discovered the plant in college and later realized its therapeutic potential through his work in the biopharmaceutical industry. He discusses his fascination with GW Pharmaceuticals, a company that successfully transformed cannabis into an FDA-regulated medicine. This engaging conversation sheds light on the journey that led Seth to become a respected figure in the cannabis space.[00:03:17] Late bloomer and cannabis use.[00:04:18] Cannabis use and legality.[00:09:03] Investment strategy and failures.[00:13:57] Frustration and finding success.[00:19:18] Cannabis industry's future and challenges.[00:20:48] Challenges in the cannabis industry.[00:24:12] Social justice inequality in cannabis.[00:29:17] Cannabis legalization and conspiracy theories.[00:32:25] Sensitization of cannabis with kids.[00:35:42] Authenticity and LinkedIn growth.[00:38:48] Using social media for business.[00:42:49] Honest voices in the industry.Subscribe and share this episode with someone who loves the CannaBiz!
What this episode covers
In this episode of CannaBiz Conversations, host Sean Welsh interviews Seth Yakatan, a prominent figure in the cannabis industry. Seth shares his cannabis origin story, recounting how he first discovered the plant in college and later realized its therapeutic potential through his work in the biopharmaceutical industry. He discusses his fascination with GW Pharmaceuticals, a company that successfully transformed cannabis into an FDA-regulated medicine. This engaging conversation sheds light on...
NOW PLAYING
From Biopharma to Cannabis:The Intersection of Pharma and Pot with Seth Yakatan
No transcript for this episode yet
Similar Episodes
May 3, 2026 ·119m
Apr 12, 2026 ·77m
Apr 11, 2026 ·88m
Apr 6, 2026 ·55m